| Nov 21 |
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
|
| Nov 21 |
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
| Nov 21 |
We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
|
| Nov 21 |
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
|
| Nov 21 |
AstraZeneca upgraded to Neutral from Sell at UBS
|
| Nov 21 |
AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
|
| Nov 20 |
AstraZeneca raised to neutral at UBS despite China headwinds
|
| Nov 20 |
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
|
| Nov 20 |
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
|
| Nov 20 |
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades
|
